Nice Morning- Safety and Efficacy Observational Study of Telmisartan in Hypertensive Patients in Multicenters

This study has been completed.

First Received: January 31, 2008 Last Updated: January 29, 2009 History of Changes

Sponsor:	Boehringer Ingelheim Pharmaceuticals
Information provided by:	Boehringer Ingelheim Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT00615108

Purpose

The purpose of this observational study is to survey the safety and effectiveness of the product under the real condition of usual practice in Taiwanese hypertensive patients. During the 8-week observation, the safety profiles and the clinical evaluation in between doses through blood pressure (BP) measurement for overall effectiveness of telmisartan therapy will be concluded.

Condition
Hypertension

Study Type:	Observational
Official Title:	Safety and Effectiveness of Micardis Tablets Taken Once Daily at 40 mg/Day and 80 mg/Day in Hypertension Patients

Resource links provided by NLM:

MedlinePlus related topics: High Blood Pressure

Drug Information available for: Telmisartan

U.S. FDA Resources

Further study details as provided by Boehringer Ingelheim Pharmaceuticals:

Enrollment:	3002
Study Start Date:	December 2006
Primary Completion Date:	December 2008 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	20 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male or female.
Aged 20 to 80 years old.
Patients meet one of following two criteria:
- Adult essential hypertensive either newly diagnosed and untreated, or previously treated and uncontrolled patients; sitting blood pressure: systolic BP > 140 mmHg but < 180 mmHg, and/or diastolic BP > 90 mmHg but < 110 mmHg).
- Patients who are assessed to benefit from the intake of angiotensin II receptor blocker (ARB) monotherapy or as add-on medication.

Exclusion Criteria:

Patients with contraindications to telmisartan use (as per the Micardis® Tablets package insert).
Known hypersensitivity to the active ingredient or to any of the excipients of Micardis® Tablets.
Any other clinical condition which, in the opinion of the attending physician, would not allow safe administration of the study medications.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00615108

Locations

Taiwan
Boehringer Ingelheim Investigator Site
Changhua, Taiwan
Boehringer Ingelheim Investigator Site 1
Chiayi, Taiwan
Boehringer Ingelheim Investigator Site 2
Chiayi, Taiwan
Boehringer Ingelheim Investigator Site
Keelung, Taiwan
Boehringer Ingelheim Investigator Site
Ksohsiung, Taiwan
Boehringer Ingelheim Investigator Site
Miaoli, Taiwan
Boehringer Ingelheim Investigator Site 1
Taichung, Taiwan
Boehringer Ingelheim Investigator Site 2
Taichung, Taiwan
Boehringer Ingelheim Investigator Site 7
Taipei, Taiwan
Boehringer Ingelheim Investigator Site 2
Tainan, Taiwan
Boehringer Ingelheim Investigator Site 1
Taipei, Taiwan
Boehringer Ingelheim Investigator Site 2
Taipei, Taiwan
Boehringer Ingelheim Investigator Site 3
Taipei, Taiwan
Boehringer Ingelheim Investigator Site 4
Taipei, Taiwan
Boehringer Ingelheim Investigator Site 5
Taipei, Taiwan
Boehringer Ingelheim Investigator Site 6
Taipei, Taiwan
Boehringer Ingelheim Investigator Site 1
Tainan, Taiwan

Sponsors and Collaborators

Boehringer Ingelheim Pharmaceuticals

Investigators

Study Chair:

Boehringer Ingelheim

Boehringer Ingelheim Pharmaceuticals

More Information

No publications provided

Responsible Party:	Boehringer Ingelheim ( Boehringer Ingelheim, Study Chair )
Study ID Numbers:	502.519
Study First Received:	January 31, 2008
Last Updated:	January 29, 2009
ClinicalTrials.gov Identifier:	NCT00615108 History of Changes
Health Authority:	Taiwan: Department of Health Taiwan

Additional relevant MeSH terms:

Vascular Diseases
Cardiovascular Diseases
Hypertension

ClinicalTrials.gov processed this record on November 20, 2009